For patients navigating treatment-resistant depression, Spravato has become one of the most meaningful advancements in modern psychiatric care. At Resiliency Mind + Body Medicine in Orange County, the treatment is delivered within a medically supervised, highly structured framework designed to support both safety and meaningful clinical outcomes. Patients often arrive with understandable questions about what the experience will entail, how Spravato differs from traditional antidepressants, and what they should expect throughout their first session. This guide is designed to provide clear, credible insight into the treatment process so patients feel informed, supported, and prepared.
Spravato (esketamine) is an FDA-approved medication for adults with treatment-resistant depression or major depressive disorder with acute suicidal ideation. Unlike oral antidepressants that work through gradual neurochemical shifts over several weeks, Spravato engages the brain’s glutamatergic system through NMDA receptor modulation. This mechanism supports rapid neuroplastic changes, often allowing patients to experience relief on a much shorter timeline. At Resiliency Mind + Body Medicine, this science-driven approach is paired with a compassionate, patient-centered clinical model to ensure each individual receives highly personalized care.